Mission Statement, Vision, & Core Values of SIGA Technologies, Inc. (SIGA)

What drives a company that achieved $133 million in product sales in 2024, marking the second consecutive year of growth? Have you ever wondered about the guiding principles behind SIGA Technologies, Inc., a commercial-stage pharmaceutical company that reported $70 million in pre-tax operating income in the same year?

Understanding a company's mission, vision, and core values provides insight into its strategic direction and operational philosophy. Keep reading to explore the foundational elements that shape SIGA's approach to biopharmaceutical innovation and market expansion.

SIGA Technologies, Inc. (SIGA) An Overview of

SIGA Technologies, Inc. (SIGA), is a commercial-stage pharmaceutical company focused on health security, that develops and commercializes solutions for infectious diseases and other health security threats. Established in 1995 and headquartered in New York, SIGA has dedicated itself to addressing significant unmet needs in the prevention and treatment of life-threatening infectious diseases. Its primary focus is on the development and commercialization of medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats, as well as emerging infectious diseases.

SIGA's flagship product is TPOXX® (tecovirimat), an antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is the only FDA-approved drug for this indication, and it holds a unique position in the market as a critical component of the U.S. strategic national stockpile. As of April 2025, SIGA continues to generate revenue primarily through government contracts for the procurement and maintenance of TPOXX in national stockpiles. The company also actively pursues international sales and partnerships to expand the availability of its products globally.

As of the latest financial reports in 2024, SIGA Technologies has demonstrated robust financial performance, marked by record-breaking revenue. Here are some key highlights:

• Record Revenue: SIGA reported record revenue, primarily driven by sales of TPOXX.
• TPOXX Sales: A significant portion of the revenue was attributed to TPOXX sales, indicating its pivotal role in the company's financial success.
• Market Growth: SIGA has experienced growth in key markets, reflecting the increasing demand for its health security solutions.

SIGA Technologies stands as a leading company in the health security sector, playing a crucial role in safeguarding public health against biological threats. Want to understand the factors behind SIGA's success? Find out more here: SIGA Technologies, Inc. (SIGA): History, Ownership, Mission, How It Works & Makes Money

SIGA Technologies, Inc. (SIGA) Mission Statement

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security, dedicated to developing and commercializing solutions for unmet medical needs and threats. They are known for their work in creating medical countermeasures against biological, chemical, radiological, and nuclear attacks.

SIGA's mission is centered around:

• Securing the integrity of critical OT processes by delivering AI-enhanced monitoring and in-depth operational perception.
• Developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs.
• Partnering with governments, commercial organizations, foundations, and others who share responsibility for global health security.

SIGA's main product is TPOXX (Tecovirimat-SIGA), a treatment for smallpox. While smallpox has been eradicated, there's a real risk it could be re-engineered as a biological weapon. TPOXX is also approved for treating monkeypox, cowpox, and complications from the vaccinia virus.

The company's corporate strategy focuses on:

• Delivering long-term shareholder value.
• Continuing partnership with the U.S. Government.
• Advancing regulatory approvals for TPOXX in new indications and formulations.
• Cultivating strategic partnerships to expand global access to TPOXX.
• Leveraging capabilities to move into complementary therapeutic areas.

SIGA Technologies aims to protect against severe infectious diseases. Their experienced team is passionate about innovation and public health, striving to equip governments and stakeholders with the tools to combat devastating diseases.

The vision of SIGA Technologies is to expand the boundaries of OT operations with deepened security and elevated process integrity. SIGAGUARD enables industrial, commercial, and critical infrastructure operators to dramatically improve the reliability, safety, and cyber security of their assets – with the minimal financial or human resources and without disrupting existing Industrial Control Systems. Whether it is a cyber breach, malfunction, or misuse, SIGA ensures its customers with confidence from the source to protect their most critical assets.

In 2024, SIGA reported strong financial results, with $133 million in product sales and $70 million in pre-tax operating income, leading to $59 million in net income. These results mark the second consecutive year of product revenue growth. Key sales included approximately $100 million of oral and IV TPOXX to the U.S. Strategic National Stockpile (SNS), $10 million to the U.S. Department of Defense, and $23 million in international sales.

Explore more about SIGA Technologies, Inc. in this insightful investor profile: Exploring SIGA Technologies, Inc. (SIGA) Investor Profile: Who’s Buying and Why?

SIGA Technologies, Inc. (SIGA) Vision Statement of

To fully understand SIGA Technologies, Inc. (SIGA), it's essential to examine its mission, vision, and core values. These elements work together to define the company's purpose, goals, and guiding principles. An effective vision statement provides a roadmap for the company's future, while the mission statement outlines its present-day objectives. The core values reflect the company's ethical and operational standards. SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on health security, particularly in the field of countermeasures against biological, chemical, radiological, and nuclear threats. Its main product is TPOXX (tecovirimat), an antiviral drug developed for the treatment of smallpox. Delving into SIGA's mission, vision, and core values provides insight into its strategic direction and operational philosophy. For a deeper dive into SIGA's financial health, see Breaking Down SIGA Technologies, Inc. (SIGA) Financial Health: Key Insights for Investors.

As of April 2025, a comprehensive and officially declared vision statement for SIGA Technologies, Inc. is not readily or publicly available. Vision statements are often broadly communicated, but in some cases, companies may not emphasize them publicly. However, we can infer components of their vision from their mission statement, strategic objectives, and core values.

SIGA Technologies, Inc.'s mission is centered on the development and commercialization of solutions to fight life-threatening diseases and health security threats. This mission reflects a commitment to:

• Developing Medical Countermeasures: Creating pharmaceutical products that can address biological, chemical, radiological, and nuclear (CBRN) threats.
• Focusing on Health Security: Prioritizing solutions that protect public health and national security against emerging and established threats.
• Commercialization: Ensuring that these solutions are not only developed but also made available to those who need them through effective commercial strategies.

This mission drives SIGA’s activities and influences its strategic decisions, particularly in the context of government contracts and public health initiatives.

While specific documented core values of SIGA Technologies, Inc. might not be widely publicized, the company's actions and priorities suggest several implicit core values:

• Commitment to Public Health: Evidenced by their focus on developing treatments for diseases that pose significant threats to public health.
• Innovation: Demonstrated through their work in creating novel solutions for complex medical challenges.
• Integrity: Reflected in their dedication to meeting regulatory standards and ethical business practices.
• Collaboration: Seen in their partnerships with government agencies and other organizations to achieve common goals in health security.

SIGA Technologies, Inc.'s strategic objectives provide further insight into its vision. These objectives typically include:

• Expanding the Use of TPOXX: Pursuing additional indications and expanding the availability of TPOXX to a broader range of patients and countries. In 2024, SIGA highlighted ongoing discussions with several countries regarding potential TPOXX orders, signaling efforts to broaden its market reach.
• Securing Government Contracts: Continuing to secure contracts with the U.S. and other governments to supply medical countermeasures. For example, SIGA secured a contract valued at approximately $13.4 million from the Biomedical Advanced Research and Development Authority (BARDA) in September 2024.
• Advancing the Pipeline: Investing in research and development to expand its portfolio of medical countermeasures.
• Enhancing Shareholder Value: Implementing strategies to improve financial performance and deliver value to its shareholders.

By synthesizing SIGA Technologies, Inc.'s mission statement, inferred core values, and strategic objectives, a clearer picture of the company's implied vision emerges. While a formal vision statement may not be publicly declared, the company’s actions and strategic focus suggest a strong commitment to global health security and innovation in the field of medical countermeasures.

SIGA Technologies, Inc. (SIGA) Core Values of

While specific, formally declared core values for SIGA Technologies, Inc. are not readily available in my knowledge base as of April 2025, we can analyze the company's actions, mission, and focus to infer key principles that guide its operations. SIGA Technologies, Inc. (SIGA), a commercial-stage pharmaceutical company, focuses on health security, specializing in the development and commercialization of solutions for infectious diseases and other health threats. Breaking Down SIGA Technologies, Inc. (SIGA) Financial Health: Key Insights for Investors

Based on their activities and public statements, we can infer some of the core values that likely drive SIGA Technologies:

• Commitment to Public Health: Given their focus on developing treatments for infectious diseases, particularly those considered public health threats, a core value is likely a strong dedication to safeguarding public health.
• Innovation and Scientific Excellence: As a pharmaceutical company, innovation and a commitment to scientific rigor are essential. This includes continuous research and development to create effective solutions.
• Responsibility and Reliability: Developing medical countermeasures requires a high degree of responsibility and reliability, especially when dealing with potential biothreats. Ensuring product safety and efficacy is paramount.
• Collaboration and Partnership: Working with government agencies and other organizations is critical in their field. A value of collaboration and effective partnership is likely a key component of their success.
• Ethical Conduct and Integrity: Operating in the pharmaceutical industry, particularly in an area that intersects with national security, demands the highest ethical standards and integrity.

These inferred values align with the nature of SIGA's work and its role in addressing significant global health challenges. While not explicitly stated by the company, their actions and strategic focus suggest these principles are integral to their operations.